The major determinants mediating drug resistance in acute lymphoblastic leukemias (ALL) unresponsive to chemotherapy, are still unclear. For example, it is still unknown whether selection or induction processes are responsible for drug resistance here or whether protein kinase C (PKC) isozymes contribute to the resistant phenotype. Therefore, inducibility of resistance factors or PKC isozymes genes was examined in CCRF-CEM cells treated with diverse anticancer drugsadriamycin, camptothecin, etoposide or vincristine-at sublethal concentrations for 24 h. MDR1, MRP1, LRP and PKC isozyme α α α α, β β β 
The mechanisms of failure of anticancer chemotherapy are still poorly understood. Several factors functionally involved in the multidrug resistance (MDR) phenotype of cell lines selected in vitro have been identified, such as the MDR1/P-glycoprotein (MDR1), 1) the multidrug resistance associated protein (MRP1) 2) or the lung cancer resistance-related protein (LRP).
3) MDR cell lines selected in vitro over long periods of time mostly show stably a high expression of one of the MDR factors, often due to gene amplification. In the clinic, enhanced expression of these factors appears to be caused by upregulation of mRNA steady-state levels rather independently of gene copy numbers. [4] [5] [6] [7] [8] 9) However, a series of recent reports point to a quick response in expression at least of P-gp genes after treatment of rodent or human cells with various xenobiotics, such as carcinogens, cocarcinogens, 7, 10, 11) antineoplastic drugs, [12] [13] [14] [15] [16] differentiating agents, 17, 18) protein kinase C (PKC) activators, 19) or other stresses, e.g., heat shock. 20, 21) The phenomenon that anticancer drugs transported by the human P-glycoprotein (P-gp) induce the expression of this drug transporter gene at drug concentrations not affecting cell vitality might be especially relevant to the clinical situation. Some influence of PKC on P-gp associated MDR, either via phosphorylation of P-gp or/and via modulation of MDR1 gene expression was indicated by the work of several groups, and inhibition of PKC has been discussed as a new approach for overcoming MDR in cancer chemotherapy. 14, [22] [23] [24] The bisindolylmaleimide GF 109203X (identical with GÖ 6850) 25) shows highly selective inhibition of many PKC isozymes in vitro (IC 50 : 30-200 nM), except for the atypical isoform PKCζ (IC 50 : 6 µM), while other kinases are affected only at distinctly higher concentrations. The indolocarbazole compound GÖ 6976 is an even more selective PKC inhibitor, since only the Ca 2+ -dependent PKC isozymes are blocked, 26) together with PKCη (IC 50 =0.6 µM). As PKC isoforms are suggested to represent a part of a stress response activating for example the MDR1 gene, PKC inhibitors might be able to attenuate the activation of drug resistance-associated genes. 27) Following recent results that MDR in the clinic might be caused by multiple factors and that distinct PKC isozymes are associated with various resistance factors 7, 9) we investigated several selected MDR cell lines for gene expression of resistance factors (MDR1, MRP1 and LRP) and PKC isozymes. Furthermore, we tested several anticancer agents for the ability to induce gene expression of these resistance factors and PKC isoforms, and examined whether PKC inhibitors attenuate gene induction. In addition, we investigated the expression pattern of these genes in blasts from acute lymphoblastic leukemia (ALL) patients during first-line treatment with steroids, and in one case nonresponding to intensive chemotherapy. The results indicate that particular PKC isoforms (PKCη, θ, ζ) may at least partially abrogate the emergence of multiple drug resistance.
MATERIALS AND METHODS

Leukemic cells and cell lines
The parental human Tlymphoblastoid cell line CCRF-CEM was obtained from the American Type Culture Collection, Rockville, MD (ATCC CCL 119). The cell lines CCRF VCR100, CCRF VCR1000, CCRF ACTD400 and CCRF ADR5000 are corresponding resistant cell lines, selected and permanently cultured in the presence of 100 or 1000 ng/ml of vincristine (VCR), 400 ng/ml of actinomycin D (ACTD) or 5000 ng/ml of adriamycin (ADR).
28) The cell lines were routinely checked for the absence of mycoplasma infection with a mycoplasma detection kit (Boehringer, Mannheim, Germany).
Blasts from patients (1 common ALL, 1 T-ALL) with remarkable, initial high blast count numbers (300 000-500 000/µl) were obtained daily from peripheral blood aspirates during first-week induction therapy with steroids, which is given as an initial monotherapy in this time interval according to the medium risk regimen of the BFM-ALL-95 treatment protocol. 29) Both patients responded well to steroids and to further combinatorial chemotherapy and have remained in continuous complete remission for more than three years. Furthermore, we investigated blasts from a T-ALL patient nonresponding to three months of intensive chemotherapy according to the high risk regimen of the BFM-ALL-95 treatment protocol. 29) This patient received combinatorial chemotherapy including ADR, asparaginase, cyclophosphamide, cytosine-arabinoside, dexamethasone, etoposide, methotrexate, prednisolone, 6-mercaptopurine, VCR and vindesine before blasts were newly drawn from bone marrow aspirates in a final stage of progression. This patient died from progressive disease four months after initial diagnosis.
Mononuclear cells were isolated by the standard FicollHypaque technique (Lymphoprep, Nycomed, Oslo/ Norway), washed twice with phosphate-buffered saline (PBS), immediately lysed with guanidinium isothiocyanate or frozen in the presence of 7% dimethylsulfoxide (DMSO) and 50% fetal calf serum (FCS) under controlled conditions, and stored in liquid nitrogen. An aliquot of mononuclear cells isolated was tested for its content of blasts. Probes with less than 95% of blasts were excluded from further analysis. Cell count and determination of vital cells were performed using a Neubauer hemacytometer chamber and staining with trypan blue. Drugs GF 109203X (GÖ 6850), GÖ 6976 and staurosporine (STAU) 30, 31) were purchased from Calbiochem (Bad Soden, Germany). Camptothecin (CAM) and ACTD were obtained from Sigma (Deisenhofen, Germany). The other drugs were taken as ready-prepared solutions for clinical use: ADR ("Adriblastin," Pharmacia & Upjohn, Erlangen, Germany), ETO (etoposide, "Vepesid," Bristol-Myers Squibbs, Troisdorf, Germany) and VCR ("Vincristin Liquid," Lilly, Bad Homburg, Germany). All other chemicals, supplies and tissue culture media were of the purest grade available, purchased from commercial sources. Cell cycle analysis At the end of induction experiments 100 000 cells were fixed in 500 µl of 70% ethanol at 4°C overnight and than stained in 500 µl of a solution containing 5 mg/ml propidium iodide and 10 mg/ml RNAse. Cells (20 000) from each experiment were measured in a flow cytometer (FACS-Calibur, Becton Dickinson, Heidelberg, Germany). Histograms were analyzed with Cell Quest software (Becton Dickinson). Experiments were carried out in triplicate. The distribution of cell cycle phases after cytostatic drug treatment is shown in Fig. 5 . Induction experiments To analyze the induction of the genes of interest we treated CCRF-CEM cells in strictly the same manner. Cells were seeded into 6-well plates at a cell density of 1×10 6 /ml for 24 h with or without drugs as indicated. An 8 h treatment showed variable results (data not shown). We used the following drug concentrations: 10, 30 and 100 ng/ml ADR; 3, 10 and 30 ng/ml CAM; 300, 1000 and 3000 ng/ml ETO and 3, 10 and 30 ng/ml VCR. Cells showed a viability greater than 90% after 24 h incubation with these compounds. This seems to be an important prerequisite to avoid measuring short-term selection effects instead of induced gene expression. After the times indicated, cells were washed twice with PBS and immediately lysed with a 4 M solution of guanidinium isothiocyanate according to Chirgwin et al. 32) Treatment with protein kinase inhibitors To test the potential of various protein kinase inhibitors to suppress gene induction of the resistance factors we preincubated cells for 4 h with 30 nM STAU, 1 µM GÖ 6976 or 5 µM GÖ 6850 before adding the cytostatic agents for an additional 24 h. In these experiments cDNA-PCR was performed exclusively for MDR1, MRP1 and LRP gene expression (Fig. 8) . The viability of cells after coincubation was in the range from 60 to 90%. cDNA-PCR gene expression analysis The preparation of total cellular RNA, the synthesis of cDNA using random hexanucleotide primers and RAV2 reverse transcriptase, and the cDNA-PCR using MDR1, MRP1, LRP, PKCα, β 1 , β 2 , ε, ι, η, θ, ζ and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specific amplimers were performed as recently described. 6, 9) The conditions for PCR though, were modified. We used "Ampli Taq Gold" DNA polymerase (Perkin Elmer, Applied Biosystems, Weiterstadt, Germany), and took 45 µl of each PCR product for polyacrylamide gel electrophoresis (Fig. 1) . PCR was carried out in the exponential range throughout. Therefore we used the following cycle numbers: GAPDH, 18; MDR1, 27; MRP1, 24; LRP, 26; PKCα, 27; PKCβ 1 , 29; PKCβ 2 , 24; PKCε, 27; PKCι, 24; PKCη, 24; PKCθ, 24; PKCζ, 29. PCR reaction mixtures of the reference gene GAPDH and the genes of interest were combined and precipitated with ethanol and 1/10 volume of 3 M sodium acetate, pH 5.2. The precipitate was dissolved in loading buffer at 60°C/10 min. PCR products were separated by polyacrylamide gel electrophoresis and stained with ethidium bromide. Signals of interest were directly digitalized using the CS1-video imager (Cybertech, Berlin, Germany) and densitometrically analyzed by the "WINCAM" software (Cybertech) 2. MDR1, MRP1 , LRP, PKCα, β 1 , β 2 , ε, ι, η, θ, ζ gene expression in the T-lymphoblastoid cell line CCRF-CEM and corresponding resistant cell lines CCRF VCR100, CCRF VCR1000, CCRF ACTD400 and CCRF ADR5000 selected and permanently cultured in the presence of 100 or 1000 ng/ml of vincristine (VCR), 400 ng/ml of actinomycin D (ACTD) or 5000 ng/ml of adriamycin (ADR). CCRF-CEM, CCRF VCR100, CCRF VCR1000, CCRF ACTD400, CCRF ADR5000.
fore calculated from an overall of 9 PCR reactions. Finally, values were referred to the untreated control which was arbitrarily set at 1.0. Statistics We performed variance analyses using JMP statistic software (SAS, Heidelberg, Germany) to determine if a factor (cytostatic agent or PKC inhibitor) exhibited a significant (P<0.05) effect on variables (expression of gene of interest).
RESULTS
Expression analysis of multidrug resistance associated genes (MDR1, MRP1, LRP) and PKC isozymes (α, β 1 , β 2 , ε, ζ, η, θ, ι) in a series of VCR, ACTD or ADR-selected CCRF-CEM T-lymphoblastoid cell lines compared to the parental cell line revealed enhanced expression of the MDR1 and the majority of PKC isozyme genes (Fig. 2) . A highly significant correlation between level of drug resistance, MDR1 gene expression and PKCη was seen. For PKCη, in the meantime, quantitative TaqMan PCR was established. The data correspond well with those from our semiquantitative PCR approach (Gekeler et al., data not shown). Interestingly, PKCα was not detectable in the CCRF subline VCR1000 (Fig. 2) but is overexpressed in CCRF ADR5000, which corresponds well with PKCα protein levels previously determined by western blot analysis.
33)
A 24 h incubation of CCRF-CEM with ADR, CAM, ETO or VCR revealed significant dose-dependent and mostly combined induction of the MDR1, MRP1 and LRP genes (Fig. 3) . No significant effects were seen for MRP1 after treatment with ADR or LRP after treatment with VCR (Fig. 3) .
The majority of PKC isozyme genes were found to be highly induced when CAM was used, while only PKCβ 1 , but interestingly not PKCβ 2 , was downregulated. PKCζ was generally upregulated by each anticancer drug applied in this setting (Fig. 4) . Cell cycle analysis revealed an enhancement of cells in S and/or G2/M. However, a correlation of distinct cell cycle distribution and gene expression pattern was only seen when CAM or ETO was used. Exposure to these cytostatics in a range of sublethal concentrations caused a shift to reduced number of cells in the G2/M-phase and enhanced number of cells in the S-phase of the cell cycle after 24 h. This was found to be correlated with marked induction of resistance factors and PKC isozymes (Fig. 5) .
Furthermore, blasts from two ALL patients during firstline therapy with steroids revealed a combined induction of resistance factors, predominantly MDR1, and various PKC isozymes, preferentially PKCζ (Fig. 6) .
Blasts of a patient with T-ALL, non responding to four months of intensive chemotherapy, drawn in a final stage of the disease, showed an enhanced MRP1 but not MDR1 or LRP gene expression combined with marked overexpression of the PKCη and θ isozymes (Fig. 7) .
The induction of the resistance factor genes (MDR1, MRP1 and LRP) in the CCRF-CEM cell line could significantly be suppressed by STAU, a rather unspecific inhibitor of protein kinases inhibiting most of the PKC isozymes. Specific inhibitors of mainly calcium-dependent PKCα, β 1,2 , η isozymes (indolocarbazole GÖ 6976) and also of PKCε, δ, η or θ (bisindolylmaleimide GÖ 6850) produced no significant effects here (Fig. 8) .
DISCUSSION
Gene expression analysis at the mRNA level by cDNA-PCR reveals the relative activity of genes, not of gene products. Thus, our work only gives circumstantial evidence for functional overexpression of drug transporters or PKC isozymes. Nonetheless, a recent report states that PKC expression is mainly regulated at the transcriptional level in hematopoietic cells. 34) We ourselves found a very good correlation between PKCα mRNA levels monitored by cDNA-PCR and the PKCα protein content estimated by western immunoblotting in preparations of a series of cell lines of different origin, 33) pointing to the value of cDNA-PCR measurements. Our study based on gene expression data should therefore be considered as evaluative to find possible targets to overcome drug resistance, and will require confirmation at the functional level in future work.
DNA intercalators such as ADR, and topoisomerase II inhibitors such as ADR and ETO, as well as the tubulinaffecting compound VCR, are known to be involved in Pgp or MRP1-associated MDR phenotypes, but the topoisomerase I inhibitor CAM is not. 35, 36) However, the antineoplastic agents used here generally show significant and dose-dependent induction of the MDR genes in CCRF-CEM cells after 24 h (Fig. 3) . CAM was found most effective in inducing the MDR1, MRP1 and LRP genes. The fact that we used sublethal concentrations of cytostatics for a short time resulted in cell viability greater than 90% at the end of each experiment, so the effects found by cDNA-PCR should not be due to short-term selection of cells showing enhanced gene expression beforehand.
Furthermore, cell cycle analysis showed that marked induction of resistance factors and PKC isozymes after incubation with CAM and ETO is correlated with a reduced number of cells in G2/M-phase and an enhanced number of cells in the S-phase. If genes in fact are inducible to a higher extent during S-phase or if enhanced activity of, for example, distinct PKC isozymes might cause this shift is presently unclear.
Furthermore, experiments with the protein kinase inhibitor STAU revealed a significant suppression of induction of MDR genes mediated by CAM or ETO, though GÖ 6976 or GÖ 6850 alone produced non-significant effects here. Moreover, no significant effects were caused by any of these substances including STAU on ADR or VCRmediated MDR1, MRP1 or LRP gene induction (data not shown).
The findings suggest that not only the MDR1, but also the MRP1 and LRP genes are inducible by various antineoplastic agents in the cell line CCRF-CEM. The effective suppression of induction by the nonspecific protein kinase inhibitor STAU, but not by the rather specific PKC inhibitors GÖ 6976 or GÖ 6850 in the experiments using CAM or ETO, where resistance factors and PKC isozymes were remarkably induced, indicates that protein kinases are involved in the complex stress response. The data do not support the involvement of PKC or particular PKC isozymes. Although GÖ 6850 and GÖ 6976 might be ineffective in inhibiting a PKC such as PKCζ under the conditions applied, our observation that ADR or VCR-mediated MDR1 gene induction cannot be suppressed either by STAU or by GÖ 6850 or GÖ 6976 points to mechanisms different from ETO-or CAM-mediated ones. Furthermore, antagonistic effects between different PKC isozymes have to be taken into account. Interestingly, it was recently shown that LRP mRNA can be induced by TPA or cytarabine (Ara C). Furthermore, LRP induction by phorbol 12-myristate 13-acetate (TPA) can be prevented with a bisindolylmaleimide PKC inhibitor, but induction by Ara C cannot. The authors noted that the LRP gene seems to be activated by different mechanisms, some of which involve PKC. 37) If mechanisms beside PKC might contribute to induction of resistance factors, this would explain the difference between the action of VCR and ADR compared to CAM and ETO.
A major goal in the field of cancer chemotherapy is to define the mechanisms underlying transcriptional regulation of drug resistance genes in an attempt to specify targets for therapeutic intervention. Our analysis points to distinct PKC isozymes as possible targets. PKCζ, in particular, was found to be inducible in CCRF-CEM by four different cytostatics and upregulated in two patients during first-line therapy with steroids.
Enhanced expression of PKCη and θ was detectable in highly resistant leukemic blasts of a T-ALL patient and, furthermore, in various selected CCRF-CEM sublines correlating to the grade of resistance and MDR1 gene expression. Furthermore, an earlier study on resistance factors and PKC isozymes in primary and relapsed states of acute myelogenous leukemias (AML) revealed enhanced MDR1, MRP and PKCθ gene expression levels in relapses of AML compared to the primary forms and significant correlations between MDR1 or MRP1 and PKCη or PKCθ gene expression. 38) In summary, we suggest that PKC isozymes η, θ and ζ should be considered as possible targets to overcome drug resistance in ALL.
